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Look Back
lfred P. Fishman, MD
hiladelphia, Pennsylvania
For the first half of the twentieth century, the published reports on primary pulmonary
hypertension (PPH) were confined to clinical pathological correlations. In the 1950s the
physiological aspects began to be reported followed by epidemiologic studies triggered by an
epidemic of PPH due to the ingestion of an appetite suppressant, aminorex fumarate. The
epidemic prompted a series of meetings of the World Health Organization, which led, in
turn, to the creation of the U.S. Registry of Primary Pulmonary Hypertension, standardiza-
tion of nomenclature, and an etiologic classification of all types of pulmonary
hypertension. (J Am Coll Cardiol 2004;43:2S–4S) © 2004 by the American College of
Cardiology Foundationt
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lor more than a century before pulmonary arterial pressures
ould be measured directly in humans, pulmonary arterio-
clerosis was widely accepted as the morphologic signature
f chronic pulmonary arterial hypertension (PAH) (1,2). In
891, Ernst von Romberg, a German physician, was puz-
led by his inability to discover at autopsy the etiology of the
ulmonary vascular lesions, which he designated as “pulmo-
ary vascular sclerosis.” Light began to be shed on the
orresponding clinical syndrome in 1901, when Dr. Abel
yerza, Professor of Medicine at the University of Buenos
ires, Argentina, lectured on the syndrome of chronic
yanosis, dyspnea, and polycythemia, which was associated
ith sclerosis of the pulmonary artery. This syndrome was
ubsequently designated as Ayerza’s disease by one of his
tudents, Dr. F.C. Arrillaga.
The first reports of the disease now know as “primary
ulmonary hypertension” (PPH) were clinical-pathological
orrelations (1–7). These were followed by speculations
oncerning etiology. They began in 1913 with Dr. Arrillaga,
ho attributed the disease to syphilitic pulmonary endarte-
itis. This misconception spurred a controversy about the
tiologic role of the spirochete, which lasted for two decades
hen the theory of a syphilitic etiology was laid to rest by
scar Brenner, a British physician who searched the liter-
ture and the Pathology Department of the Massachusetts
eneral Hospital for clues to etiology (8). Based on pub-
ished accounts of Ayerza’s disease, coupled with his own
bservations, Dr. Brenner concluded that so-called Ayerza’s
isease was neither a clinical nor a pathological entity.
nstead, he concluded accurately that the clinical manifes-
ations of so-called Ayerza’s disease were those of heart
ailure secondary to pulmonary disease, and he interpreted
he pathological findings as morphologic evidence of
hronic pulmonary disease, moderate pulmonary atheroscle-
osis, and right ventricular hypertrophy. He saw no reason
or the term “Ayerza’s disease.” However, he did fail to see
From the University of Pennsylvania School of Medicine, Philadelphia, Pennsyl-
ania.
Manuscript received November 26, 2003; revised manuscript received March 2,
o004, accepted March 8, 2004.he connection between the pulmonary vascular disease and
he right ventricular hypertrophy, picturing each as a sepa-
ate entity due to “an unknown cause.” Another half-century
as to go by before histopathology of the disease was
larified and the relationships between the pulmonary vas-
ular lesions and the right ventricular hypertrophy were
learly understood (9).
Postmortem studies of the pulmonary vasculature in the
930s could provide little insight into the functional behav-
or of the pulmonary resistance vessels (i.e., the small
uscular pulmonary arteries and arterioles) during life. The
unctional aspects began to be explored in the 1940s by
xperiments in cats and humans, which showed that acute
ypoxia (10% O2 in N2) elicits pulmonary vasoconstriction
10–12). In 1951, Dresdale, Michtom, and Schultz (13)
ook the opposite tack (i.e., to relieve pulmonary hyperten-
ion): in patients with PPH they showed that tolazoline
Priscoline), a pulmonary vasodilator, relieved pulmonary
ypertension. However, the observation was not entirely
onvincing because tolazoline is not only a pulmonary
asodilator but also a systemic vasodilator, raising the
ossibility that the effect on the pulmonary circulation was
econdary to systemic vasodilation.
To eliminate this uncertainty, Harris et al. resorted to the
ntravenous injection of acetylcholine, which is destroyed
uring a single passage through the lungs (14,15). They
ound that acetylcholine was virtually without effect on the
ulmonary circulation during normoxia (i.e., while breath-
ng ambient air) but elicited pulmonary vasodilation if
ulmonary vascular tone was previously increased by expos-
ng the subject to a hypoxic-inspired air mixture. Soon
hereafter, Wood et al. (16) showed that the intravenous
njection of acetylcholine also elicited pulmonary vasodila-
ion in patients with pulmonary hypertension secondary to
itral stenosis.
Such was the state of morphological and physiological
nowledge relating to PPH when the epidemic of
minorex-induced pulmonary hypertension broke out in the
ate 1960s (17). Aminorex fumarate (2-amino-5-phenyl-2-
xazoline) is a catechol derivative, which was sold as an
o
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June 16, 2004:2S–4S A Perspective on PAHver-the-counter appetite suppressant to promote weight
oss. Its actions include release of norepinephrine at nerve
ndings and an increase in levels of serotonin in the
irculation. The drug was introduced on the Swiss, German,
nd Austrian markets in November 1965 and was with-
rawn in October 1968 because it was held responsible for
n epidemic of pulmonary hypertension. In patients who
ied from aminorex pulmonary hypertension, the pulmo-
ary vascular lesions were identical with those of PPH. The
minorex outbreak presented two major questions about the
athogenesis of PPH. The first, stemming from the fact
hat only a few individuals who took the drug developed
ulmonary hypertension, raised the possibility that genetic
redisposition played a role in the pathogenesis of the
isease (18). The second question was concerned with
ncertainties about initiating and pathogenetic mechanisms.
HE FIRST WORLD HEALTH ORGANIZATION (WHO)
EETING, GENEVA, 1973
rompted by the outbreak of aminorex-induced pulmonary
ypertension, the WHO convened a group of experts in
973 to assess the state of knowledge about PPH and to
tandardize clinical and pathological nomenclature (19). In
ddition to accomplishing these goals, the 1973 meeting
alled for an international registry that would gather stan-
ardized data about the rare disease.
HE NATIONAL REGISTRY, 1981
he international registry did not materialize. However, in
981, the National Heart, Lung and Blood Institute of the
ational Institutes of Health created a National Registry of
atients with PPH (20). The Registry consisted of three
omponents: a statistical-epidemiological core, a pathology
ore, and 32 clinical centers. By the time the Registry closed
n 1987, it had accomplished more than anticipated with
espect to the elucidation of the clinical, pathophysiologic,
nd morphologic features of the disease (21). Moreover, the
articipants, gratified by the success of this collaborative
ffort, subsequently embarked upon other clinical trials.
HE SECOND WHO MEETING, EVIAN, FRANCE, 1998
he second WHO meeting, on the 25th anniversary of the
riginal meeting in Geneva, went beyond the confines of
PH. Instead, it undertook to compile a classification of all
ulmonary hypertensive diseases. The detailed classification
ppears in Table 1. Here it will suffice to indicate that it
orts all types of pulmonary hypertensive diseases into five
Abbreviations and Acronyms
PAH  pulmonary arterial hypertension
PPH  primary pulmonary hypertension
WHO  World Health Organizationategories: 1) PAH 2) pulmonary venous hypertension, 3) uAH associated with disorders of the respiratory system or
ypoxemia, 4) PAH caused by chronic thrombotic or
mbolic disease, and 5) PAH cased by disorders of the
ulmonary vasculature (22–27).
HE THIRD WORLD SYMPOSIUM ON PULMONARY
RTERIAL HYPERTENSION, VENICE, 2003
he third World Symposium on PAH was prompted by a
emarkable surge in the understanding of the mechanisms
nvolved in the pathogenesis of pulmonary hypertension
hat occurred during the few years after the 1998 session.
hese advances covered a broad span, ranging from molec-
able 1. The Evian Classification
. Pulmonary arterial hypertension
1.1 Primary pulmonary hypertension
(a) Sporadic
(b) Familial
1.2 Related to
(a) Collagen vascular disease
(b) Congenital systemic-to-pulmonary shunts
(c) Portal hypertension
(d) Human immunodeficiency virus infection
(e) Drugs/toxins
(1) Anorexigens
(2) Other
(f) Persistent pulmonary hypertension of the newborn
(g) Other
. Pulmonary venous hypertension
2.1 Left-sided atrial or ventricular heart disease
2.2 Left-sided valvular heart disease
2.3 Extrinsic compression of central pulmonary veins
(a) Fibrosing mediastinitis
(b) Adenopathy/tumors
2.4 Pulmonary veno-occlusive disease
2.5 Other
. Pulmonary hypertension associated with disorders of the respiratory
system or hypoxemia
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Sleep-disordered breathing
3.4 Alveolar hypoventilation disorders
3.5 Chronic exposure to high altitude
3.6 Neonatal lung disease
3.7 Alveolar-capillary dysplasia
3.8 Other
. Pulmonary hypertension caused by chronic thrombotic or embolic
disease
4.1 Thromboembolic obstruction of proximal pulmonary arteries
4.2 Obstruction of distal pulmonary arteries
(a) Pulmonary embolism (thrombus, tumor, ova or parasites, foreign
material)
(b) In situ thrombosis
(c) Sickle cell disease
. Pulmonary hypertension caused by disorders directly affecting the
pulmonary vasculature
5.1 Inflammatory
(a) Schistosomiasis
(b) Sarcoidosis
(c) Other
5.2 Pulmonary capillary hemangiomatosislar biology, developmental biology, and genetics on the one
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A Perspective on PAH June 16, 2004:2S–4Sand, to clinical trials, natural history, and epidemiology on
he other.
The third World Symposium on PAH also provided an
pportunity to review the effectiveness of the Evian diag-
ostic classification. To this end, 14 experts from the U.S.
nd abroad were asked to review critically the Evian diag-
ostic classification with respect to its value for clinical,
esearch, and epidemiologic purposes. Virtually all partici-
ants agreed that the classification was primarily useful for
linical and epidemiologic purposes and less so for research.
his pattern of response was not unexpected as research has
ecome increasingly devoted to the molecular and develop-
ental aspects of the disease, whereas the classification is
ocused on diagnosis and treatment.
ONCLUDING COMMENTS
rogress in the understanding of PPH has catalyzed the
lassification of all pulmonary hypertensive diseases. The
tiologic basis for the classification enhances the prospects
or a unified approach to diagnosis and therapy.
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enior Associate Dean, University of Pennsylvania School of
edicine, 423 Guardian Drive, 1320 Blockley Hall, Philadelphia,
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